Overview of anti-viral effects of probiotics via immune cells in pre-, mid- and post-SARS-CoV2 era

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Dec. 5, 2023

The COVID-19 outbreak has caused significant global changes and increased public awareness of SARS-CoV-2. Substantial progress in developing vaccines, enhancing sanitation practices, implementing various measures to combat the virus, including utilization probiotics been made. This comprehensive review examined medical impact clinically proven on infectious diseases, considering three crucial time periods: before (pre-), during (mid-), after (post-) pandemic era. also showed a perspective use stimulate innate immune system prevent diseases. In pre-COVID-19 era, several probiotic strains were found be effective addressing gastrointestinal common cold flu. However, mechanism by which exerted their antiviral effects remained relatively unclear that period. Nevertheless, probiotics, Lactococcus lactis strain Plasma (LC-Plasma), others have gained attention for unique ability modulate demonstrate properties. While some shown promise alleviating symptoms linked COVID-19, direct effectiveness treating or preventing progression not yet conclusively established. As we transition into post-COVID-19 relationship between plasmacytoid dendritic cells (pDCs), vital component system, gradually elucidated. These findings are now being applied novel vaccines treatments involving interferons activation research using as adjuvants, comparable CpG-DNA through TLR9. role local pDCs, first line defense against viral infections increasing interest. Moving forward, insight crosstalk is expected highlight adjunctive immunoregulatory therapy. combination with drug treatments, may play more substantial responses. approach such LC-Plasma, can induce anti-infectious factors interferons, holds viable therapeutic prophylactic option diseases due good safety profile protective efficacy.

Language: Английский

---

Genomic Insight into the COVID-19 Severity in MAFLD Patients: A Single-Center Prospective Cohort Study

Published: March 27, 2024

This study investigated the influence of single nucleotide polymorphisms (SNPs) in genes asso-ciated with interferon pathway (IFNAR2 rs2236757), antiviral response (OAS1 rs10774671, OAS3 rs10735079), and viral entry (ACE2 rs2074192) on COVID-19 severity their association non-alcoholic fatty liver disease (MAFLD). We did not observe a significant between SNPs severity. While IFNAR2 rs2236757 A allele correlated higher creatinine levels upon admission G lower band neu-trophils discharge, these findings require further investigation. The distribution OAS gene (rs10774671, rs10735079 differ MAFLD non-MAFLD patients. Our population's ACE2 rs2074192 genotypes alleles differed from European reference population. Overall, our suggest that specific may be major contributors to patient population, highlighting potential role other genetic factors environmental influences.

Language: Английский

---

Pharmacodynamic of Recombinant Human Interferon Alpha-2b Nasal Drops and Effective Prophylaxis Against SARS-COV-2 Infection

Journal of Interferon & Cytokine Research, Journal Year: 2024, Volume and Issue: 44(6), P. 271 - 280

Published: April 10, 2024

The recombinant human interferon alpha-2b (IFN-α2b) nasal drop formulation (Nasalferon) was studied as prophylaxis for SARS-CoV-2. Healthy volunteers between 19 and 80 years of age received 0.5 million international units IFN in one (0.05 mL ) each nostril, twice a day, 10 consecutive days. nondetection SARS-CoV-2 by real-time polymerase chain reaction the primary outcome variable. Several IFN-α biomarkers, including intranasal gene expression innate immune effector activity, were increased participants who IFN-α2b. study included 2,930 travelers 5,728 persons their close contacts. subjects treated with Nasalferon January 2021, 9,162 untreated controls. COVID-19 rate significantly lower than (0.05% vs. 4.84%). proportion decreased from 60.9% to 2.2% December 2020 February 2021. Furthermore, 1,719 tourism workers also Nasalferon, no cases infection detected, whereas 39 (10.6%) reported 367 subjects. main adverse events associated use IFN-α2b congestion, headache, rhinorrhea. Our prophylactic health interventions demonstrates that daily administration days decreases risk developing healthy volunteers. [Figure: see text].

Language: Английский

---

Unveiling risk factors for post-COVID-19 syndrome development in people with type 2 diabetes

Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 11, 2024

Introduction Post-COVID-19 syndrome (PCS) is a severe acute respiratory coronavirus 2 (SARS-CoV-2) infection-associated chronic condition characterized by long-term violations of physical and mental health. People with type diabetes (T2D) are at high risk for COVID-19 PCS. Aim The current study aimed to define the predictors PCS development in people T2D further planning preventive measures improving patient outcomes. Materials methods data were collected through national survey targeting persons concerning history course signs symptoms that developed during or after continued more than 12 weeks not explained an alternative diagnosis. In total, 469 patients from different regions Ukraine enrolled study. Among them, 227 reported (main group), while 242 did claim (comparison group). Stepwise multivariate logistic regression probabilistic neural network (PNN) models used select independent factors. Results Based on data, 8 factors associated selected: newly diagnosed (OR 4.86; 95% CI 2.55–9.28; p<0.001), female sex 1.29; 0.86–1.94; p=0.220), severity 1.35 1.05–1.70; p=0.018), myocardial infarction 2.42 1.26–4.64; p=0.002) stroke 3.68 1.70–7.96; p=0.001) anamnesis, HbA1c above 9.2% 2.17 1.37–3.43; p=0.001), use insulin analogs 2.28 1.31–3.94; p=0.003) vs human 0.67 0.39–1.15; p=0.146). Although obesity aggravated severity, it impact development. ROC analysis, 8-factor multilayer perceptron (MLP) model exhibited better performance (AUC 0.808; CІ 0.770–0.843), allowing prediction sensitivity 71.4%, specificity 76%, PPV 73.6% NPV 73.9%. Conclusions Patients who T2D, had 9.2%, previous cardiovascular cerebrovascular events, mechanical lung ventilation

Language: Английский

---

Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response

iScience, Journal Year: 2023, Volume and Issue: 26(9), P. 107631 - 107631

Published: Aug. 16, 2023

Severe infections with coronaviruses are often accompanied hyperinflammation, requiring therapeutic strategies to simultaneously tackle the virus and inflammation. By screening a safe-in-human broad-spectrum antiviral agents library, we identified that indomethacin can inhibit pan-coronavirus infection in human cell airway organoids models. Combining oral drugs authorized for treating COVID-19 results synergistic anti-coronavirus activity. Coincidentally, library of FDA-approved as most potent potentiator interferon response through increasing STAT1 phosphorylation. interferon-alpha exerted effects against multiple coronaviruses. The activity is associated activating response. In co-culture system lung epithelial cells macrophages, inhibited both viral replication inflammatory Collectively, inhibitor virus-triggered potential be further augmented by combining it or interferon-alpha.

Language: Английский

---